BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 9765225)

  • 1. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells.
    Takai H; Kanematsu M; Yano K; Tsuda E; Higashio K; Ikeda K; Watanabe K; Yamada Y
    J Biol Chem; 1998 Oct; 273(42):27091-6. PubMed ID: 9765225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells.
    Murakami T; Yamamoto M; Ono K; Nishikawa M; Nagata N; Motoyoshi K; Akatsu T
    Biochem Biophys Res Commun; 1998 Nov; 252(3):747-52. PubMed ID: 9837778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel molecular mechanism modulating osteoclast differentiation and function.
    Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Goto M; Mochizuki SI; Tsuda E; Morinaga T; Udagawa N; Takahashi N; Suda T; Higashio K
    Bone; 1999 Jul; 25(1):109-13. PubMed ID: 10423033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK; Lorenzo JA
    Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.
    Yasuda H; Shima N; Nakagawa N; Yamaguchi K; Kinosaki M; Mochizuki S; Tomoyasu A; Yano K; Goto M; Murakami A; Tsuda E; Morinaga T; Higashio K; Udagawa N; Takahashi N; Suda T
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3597-602. PubMed ID: 9520411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.
    Yasuda H; Shima N; Nakagawa N; Mochizuki SI; Yano K; Fujise N; Sato Y; Goto M; Yamaguchi K; Kuriyama M; Kanno T; Murakami A; Tsuda E; Morinaga T; Higashio K
    Endocrinology; 1998 Mar; 139(3):1329-37. PubMed ID: 9492069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells.
    Kanzawa M; Sugimoto T; Kanatani M; Chihara K
    Eur J Endocrinol; 2000 Jun; 142(6):661-4. PubMed ID: 10822231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects.
    Thirunavukkarasu K; Miles RR; Halladay DL; Yang X; Galvin RJ; Chandrasekhar S; Martin TJ; Onyia JE
    J Biol Chem; 2001 Sep; 276(39):36241-50. PubMed ID: 11451955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation.
    Karst M; Gorny G; Galvin RJ; Oursler MJ
    J Cell Physiol; 2004 Jul; 200(1):99-106. PubMed ID: 15137062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of osteoclastogenesis and RANK expression by TGF-beta1.
    Yan T; Riggs BL; Boyle WJ; Khosla S
    J Cell Biochem; 2001 Aug 1-9; 83(2):320-5. PubMed ID: 11573248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway.
    Kanematsu M; Yoshimura K; Takaoki M; Sato A
    Bone; 2002 Apr; 30(4):553-8. PubMed ID: 11934645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
    J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitric oxide donor increases osteoprotegerin production and osteoclastogenesis inhibitory activity in bone marrow stromal cells from ovariectomized rats.
    Wang FS; Wang CJ; Chen YJ; Huang YT; Huang HC; Chang PR; Sun YC; Yang KD
    Endocrinology; 2004 May; 145(5):2148-56. PubMed ID: 14962990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human dental mesenchymal cells and epithelial cells.
    Sakata M; Shiba H; Komatsuzawa H; Fujita T; Ohta K; Sugai M; Suginaka H; Kurihara H
    J Bone Miner Res; 1999 Sep; 14(9):1486-92. PubMed ID: 10469276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas.
    Kumamoto H; Ooya K
    J Oral Pathol Med; 2004 Jan; 33(1):46-52. PubMed ID: 14675140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
    Takayanagi H; Iizuka H; Juji T; Nakagawa T; Yamamoto A; Miyazaki T; Koshihara Y; Oda H; Nakamura K; Tanaka S
    Arthritis Rheum; 2000 Feb; 43(2):259-69. PubMed ID: 10693864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation.
    Nagai M; Sato N
    Biochem Biophys Res Commun; 1999 Apr; 257(3):719-23. PubMed ID: 10208850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
    Kondo H; Guo J; Bringhurst FR
    J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.